Document is current

Article History

Received: 14 February 2024

Accepted: 30 September 2024

First Online: 8 October 2024

Declarations

:

: The study was performed in accordance with the German drug law (German Arzneimittelgesetz, AMG), the guidelines of the BfArM (Federal Institute for Drugs and Medical Devices), and by following all required notifications. An independent ethics committee approved the study protocol ((NCT00863655). Written informed consent was obtained from all patients.

: Not applicable.

: PZ reports personal fees from Novartis Pharma GmbH () (talks and traveling fees to present an interims analysis at the SABCS 2015) and IPSEN () (advisory board). DL, AS, TD, CM, CJ, and WB report personal fees from Novartis Pharma GmbH (). AH and TF report grants from Novartis Pharma GmbH () during the conduct of the study. SH, GG, and JK report other non-financial support from Novartis Pharma GmbH () during the conduct of the study. MS reports grants and personal fees from Novartis Pharma GmbH (). HT reports personal fees and non-financial support from Novartis Pharma GmbH (). PAF reports grants from Biontech () and Cepheid (), personal fees from Roche (), Pfizer (), Celgene (), Daiichi-Sankyo (), Astra Zeneca (), MSD (), Myelo Therapeutics (), Macrogenics (), Eisai (), Lilly (), and Puma () and grants and personal fees from Novartis Pharma GmbH () during the conduct of the study. WB reports personal fees from Novartis Pharma GmbH () during the conduct of the study. FS, KS, TE, FTB, AR, CU, and FF have nothing to disclose.